Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Penny Stock Project. -- Ignore unavailable to you. Want to Upgrade?

To: Brister who wrote (60)	9/1/2000 6:15:31 PM
From: Tadsamillionaire	Respond to of 67

AVN news.... From: stockschick 09/01/2000 07:29:24 Msg: #of 8 AVN is up 185 % in 4 months. SEPT. 1st is HERE! AVN has soared 185% since the May 1st. It seems as though shareholders are scrambling for shares before the opening of Xenerex, a newly formed division of AVN. Xenerex will open with the distinct goal of providing fully human monoclonal antibodies to Pharmacutical and Biotech companies worldwide. AVN recently formed Xenerex to compete with high flyers such as ABGX & MEDX. Both ABGX and MEDX soared earlier this year based on technology similar to AVN's. ABGX went to 400+ in the bull market (before announcing 2 splits) and MEDX soared to 200+. AVN says Xenerex will open for business Sept. 1 and they are already in discussions with possible partners. In a recent interview Gregory Hansen, Xenerex President is touting the Xenerex mouse as having great advantages over the competition. "Using immuno-deficient mice, rather than transgenic mice, Xenerex can produce completely human antibodies faster and cheaper than its competition, big market players like Abgenix Inc., Medarex Inc. and Cambridge Antibody Technology plc, Hansen said. " Bioworld Online, Aug 21, 2000 Also bear in mind that AVN will post profits next quarter due to the FDA approval of the first Over-The-Counter Herpes Cream. biz.yahoo.com avanir.com